rs2178575 — ERBB4 ERBB4/HER4 PCOS Folliculogenesis

ERBB4/HER4 — When a Signalling Receptor Shapes the Follicular Microenvironment

Inside every developing ovarian follicle, thousands of granulosa cells form a tightly coordinated network around the oocyte, communicating through gap junctions and paracrine signals to orchestrate its maturation. At the centre of this communication system sits ERBB4/HER4¹¹ ERBB4/HER4
Erb-b2 receptor tyrosine kinase 4; a member of the epidermal growth factor receptor family that activates PI3K-AKT and MAPK/ERK signalling cascades when bound by neuregulin or betacellulin ligands, a receptor whose deletion in granulosa cells dismantles the structural integrity of the follicle itself. The rs2178575 variant is an intronic tag SNP in ERBB4 on chromosome 2q34 — a locus confirmed at genome-wide significance in multiple independent PCOS cohorts.

The Mechanism

The rs2178575 A allele tags regulatory variation that modulates ERBB4 expression or splicing in granulosa cells; the precise functional variant has not yet been isolated. The biological consequence of reduced ERBB4 signalling in this context was made clear by a 2020 conditional knockout study: Veikkolainen et al. 2020²² Veikkolainen et al. 2020
Erbb4 regulates the oocyte microenvironment during folliculogenesis. Hum Mol Genet 29:2903–2916 showed that mice with Erbb4 deleted specifically in granulosa cells develop profound follicular disruption. Without ERBB4 signalling, the intercellular junctions between granulosa cells and the oocyte are defective — the physical connections that allow nutrients, hormones, and growth factors to reach the developing egg. These mice displayed asynchronous oestrous cycles, markedly reduced ovulation rates, and subfertility, alongside elevated luteinising hormone, elevated androgens, and elevated anti-Müllerian hormone — a hormonal profile that closely mirrors polycystic ovary syndrome in women.

ERBB4 is one of three epidermal growth factor receptor genes (alongside ERBB2/HER2 and ERBB3/HER3) with PCOS risk associations, suggesting that granulosa-cell EGF receptor signalling as a whole is a critical pathway in PCOS aetiology.

The Evidence

The ERBB4 locus was first identified in a 2015 genome-wide association study of polycystic ovary syndrome: Day et al. 2015³³ Day et al. 2015
Causal mechanisms and balancing selection inferred from genetic associations with PCOS. Nat Commun 6:8464 analysed up to 5,184 self-reported PCOS cases and 82,759 controls of European ancestry, identifying six genome-wide significant loci, including ERBB4/2q34. The finding was independently replicated in a 2017 Han Chinese study (Peng et al. 2017⁴⁴ (Peng et al. 2017
Sci Rep 7:42888), which found a nearby ERBB4 variant (rs1351592) significantly enriched in 1,500 Chinese PCOS cases versus controls.

The ERBB4 association was confirmed and extended by the largest European PCOS GWAS meta-analysis to date: Day et al. 2018⁵⁵ Day et al. 2018
Large-scale GWAS meta-analysis of PCOS suggests shared genetic architecture. PLoS Genet 14:e1007813 meta-analysed 10,074 PCOS cases and 103,164 controls, listing rs2178575 in Table 2 as the lead ERBB4 locus SNP among 14 genome-wide significant PCOS variants. The ERBB4 locus showed particularly strong association with oligomenorrhoea/dysmenorrhoea and polycystic ovarian morphology phenotypic subgroups within the PCOS spectrum.

A small Pakistani case-control study (Samma et al. 2024⁶⁶ (Samma et al. 2024
Biochem Genet 62:2148) found that among infertile PCOS women, the GA and AA genotypes were associated with reduced infertility odds (OR 0.54 and 0.42 respectively). This population-specific result likely reflects the relationship between ERBB4-associated anovulatory PCOS and preserved ovarian reserve — a counter-intuitive finding where the anovulatory phenotype driven by ERBB4 pathway disruption still results in adequate follicular pool (high AMH, polycystic morphology) that can be recruited with IVF stimulation.

Practical Actions

The ERBB4 mechanism is follicular rather than metabolic: the primary risk is disrupted follicle maturation and anovulation, not insulin resistance or obesity. Monitoring should focus on ovulatory function and follicular architecture. Anti-Müllerian hormone and antral follicle count are the biomarkers most directly linked to ERBB4 pathway disruption — elevated AMH with polycystic morphology at ultrasound is the expected imaging signature.

Neuregulin-1 and betacellulin, the natural ligands for ERBB4, are partially regulated by omega-3 fatty acids and antioxidant status. There is no direct clinical trial data on supplementation in this specific genotype, but the follicular oxidative stress that impairs granulosa-cell junction integrity is mechanistically relevant.

For women seeking pregnancy, the ERBB4 PCOS subtype — characterised by anovulation with preserved or elevated ovarian reserve (high AMH) — has a favourable prognosis with ovulation induction. Letrozole is the recommended first-line agent.

Interactions

ERBB4 sits in a cluster of EGF receptor-family PCOS loci. Day 2015 noted that ERBB2 (HER2) and ERBB3 (HER3) variants are also associated with PCOS at or near genome-wide significance, suggesting that the EGF receptor signalling axis in granulosa cells is broadly disrupted in the ERBB4-type PCOS.

The most clinically relevant interaction is with DENND1A (rs7852296), a second PCOS susceptibility locus that operates through a complementary mechanism — DENND1A elevation impairs FSH receptor recycling in granulosa cells, while ERBB4 reduction impairs the structural junctions that allow follicular coordination. Both affect granulosa-cell function, but via distinct pathways. Carriers of risk alleles at both loci would represent a reproductive PCOS subtype with both impaired FSH response and impaired oocyte microenvironment. No published compound effect size exists for this combination.

LH receptor variants (LHCGR rs13405728) interact at the ovulation trigger level — LHCGR function is required for the LH surge to produce ovulation, a step that is also impaired in ERBB4-associated PCOS. Both variants should be considered together when evaluating anovulatory infertility.